Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D04UUD
|
|||
| Former ID |
DCL000079
|
|||
| Drug Name |
CC-401
|
|||
| Synonyms |
CC-401; 395104-30-0; UNII-NOE38VQA1W; NOE38VQA1W; 3-(3-(2-(piperidin-1-yl)ethoxy)phenyl)-5-(1H-1,2,4-triazol-5-yl)-1H-indazole; 3-(3-(2-(piperidin-1-yl)ethoxy)phenyl)-5-(1H-1,2,4-triazol-3-yl)-1H-indazole; 3-[3-[2-(1-PIPERIDINYL)ETHOXY]PHENYL]-5-(1H-1,2,4-TRIAZOL-5-YL)-1H-INDAZOLE; CC 401; C22H24N6O; PubChem22434; SCHEMBL4604749; CHEMBL1614713; CHEBI:91437; DTXSID40192650; MolPort-044-561-531; MolPort-021-804-942; BCPP000298; BCP01960; ZINC38836256; RS0046; HY-13022A; AKOS027251057; AKOS027336636; DB12432; BCP9000495; CS-1955
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [1] | |
| Therapeutic Class |
Anticancer Agents
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C22H24N6O
|
|||
| Canonical SMILES |
C1CCN(CC1)CCOC2=CC=CC(=C2)C3=NNC4=C3C=C(C=C4)C5=NC=NN5
|
|||
| InChI |
1S/C22H24N6O/c1-2-9-28(10-3-1)11-12-29-18-6-4-5-16(13-18)21-19-14-17(22-23-15-24-27-22)7-8-20(19)25-26-21/h4-8,13-15H,1-3,9-12H2,(H,25,26)(H,23,24,27)
|
|||
| InChIKey |
XDJCLCLBSGGNKS-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 395104-30-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
15449960, 40558027, 77261940, 119527154, 125569071, 126728317, 135296756, 136368006, 142702481, 143023589, 143499574, 144081847, 144115797, 152234917, 162205118, 172650045, 172918805, 174006726, 174561052, 180371705, 198962317, 210274815, 210280448, 223669414, 230518417, 242405914, 245052403, 247905552, 247924780, 248560986, 252090127, 252160664, 252215106
|
|||
| ChEBI ID |
CHEBI:91437
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Jun N terminal kinase (JNK) | Target Info | Modulator | [2], [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | SP600125 inhibits Orthopoxviruses replication in a JNK1/2 -independent manner: Implication as a potential antipoxviral. Antiviral Res. 2012 Jan;93(1):69-77. | |||
| REF 2 | Signal integration by JNK and p38 MAPK pathways in cancer development.Nat Rev Cancer.2009 Aug;9(8):537-49. | |||
| REF 3 | Recent progress in the design, study, and development of c-Jun N-terminal kinase inhibitors as anticancer agents.Chem Biol.2014 Nov 20;21(11):1433-43. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.